OBJECTIVE: Understanding the extent to which early antiretroviral therapy (ART) can limit the establishment and persistence of the HIV reservoir is an important step to designing interventions aimed at achieving HIV cure. We measured the markers of HIV persistence and HIV-specific immunity in early treated children. DESIGN: This is a cross-sectional study that enrolled 15 children older than 2 years of age who initiated ART before 6 months of age and had sustained viral suppression. Total and integrated HIV DNA, and 2-LTR circles in CD4 T cells, HIV antibody response by fourth generation HIV enzyme immunoassay, and CD4 and CD8 T-cell responses to gag/env peptides by intracellular cytokine staining of CD4 and CD8 T cells were measured. RESULTS: The median current age was 6.3 years and age at ART initiation was 17 weeks. The median duration of viral suppression was 6 years, and all had HIV RNA less than 50 copies/ml. The median CD4 T cells was 44%. The median total HIV DNA was 132 copies/10 CD4 T cells (range 11-1804) and integrated HIV DNA was 17 copies/10 CD4 T cells (range 0-516), and no one had detectable 2-LTR circles. Nine of the 15 children (60%) had undetectable or extremely low integrated HIV DNA (<20 copies/10 CD4 T cells). All except one (93%) had undetectable HIV-specific CD4/CD8 cell responses and seven (47%) had nonreactive enzyme immunoassay. CONCLUSION: Early ART resulted in very low levels of markers of HIV persistence and undetectable HIV-specific immune responses in the majority of HIV-infected children who started ART before 6 months of age.
OBJECTIVE: Understanding the extent to which early antiretroviral therapy (ART) can limit the establishment and persistence of the HIV reservoir is an important step to designing interventions aimed at achieving HIV cure. We measured the markers of HIV persistence and HIV-specific immunity in early treated children. DESIGN: This is a cross-sectional study that enrolled 15 children older than 2 years of age who initiated ART before 6 months of age and had sustained viral suppression. Total and integrated HIV DNA, and 2-LTR circles in CD4 T cells, HIV antibody response by fourth generation HIV enzyme immunoassay, and CD4 and CD8 T-cell responses to gag/env peptides by intracellular cytokine staining of CD4 and CD8 T cells were measured. RESULTS: The median current age was 6.3 years and age at ART initiation was 17 weeks. The median duration of viral suppression was 6 years, and all had HIV RNA less than 50 copies/ml. The median CD4 T cells was 44%. The median total HIV DNA was 132 copies/10 CD4 T cells (range 11-1804) and integrated HIV DNA was 17 copies/10 CD4 T cells (range 0-516), and no one had detectable 2-LTR circles. Nine of the 15 children (60%) had undetectable or extremely low integrated HIV DNA (<20 copies/10 CD4 T cells). All except one (93%) had undetectable HIV-specific CD4/CD8 cell responses and seven (47%) had nonreactive enzyme immunoassay. CONCLUSION: Early ART resulted in very low levels of markers of HIV persistence and undetectable HIV-specific immune responses in the majority of HIV-infectedchildren who started ART before 6 months of age.
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Caroline C King; Athena P Kourtis; Deborah Persaud; Julie A E Nelson; Carrie Ziemniak; Michael G Hudgens; Gerald Tegha; Charles S Chasela; Denise J Jamieson; Charles M van der Horst Journal: AIDS Date: 2015-09-24 Impact factor: 4.177
Authors: William R McManus; Michael J Bale; Jonathan Spindler; Ann Wiegand; Andrew Musick; Sean C Patro; Michele D Sobolewski; Victoria K Musick; Elizabeth M Anderson; Joshua C Cyktor; Elias K Halvas; Wei Shao; Daria Wells; Xiaolin Wu; Brandon F Keele; Jeffrey M Milush; Rebecca Hoh; John W Mellors; Stephen H Hughes; Steven G Deeks; John M Coffin; Mary F Kearney Journal: J Clin Invest Date: 2019-07-30 Impact factor: 14.808
Authors: Steven G Deeks; Sharon R Lewin; Anna Laura Ross; Jintanat Ananworanich; Monsef Benkirane; Paula Cannon; Nicolas Chomont; Daniel Douek; Jeffrey D Lifson; Ying-Ru Lo; Daniel Kuritzkes; David Margolis; John Mellors; Deborah Persaud; Joseph D Tucker; Françoise Barre-Sinoussi; Galit Alter; Judith Auerbach; Brigitte Autran; Dan H Barouch; Georg Behrens; Marina Cavazzana; Zhiwei Chen; Éric A Cohen; Giulio Maria Corbelli; Serge Eholié; Nir Eyal; Sarah Fidler; Laurindo Garcia; Cynthia Grossman; Gail Henderson; Timothy J Henrich; Richard Jefferys; Hans-Peter Kiem; Joseph McCune; Keymanthri Moodley; Peter A Newman; Monique Nijhuis; Moses Supercharger Nsubuga; Melanie Ott; Sarah Palmer; Douglas Richman; Asier Saez-Cirion; Matthew Sharp; Janet Siliciano; Guido Silvestri; Jerome Singh; Bruno Spire; Jeffrey Taylor; Martin Tolstrup; Susana Valente; Jan van Lunzen; Rochelle Walensky; Ira Wilson; Jerome Zack Journal: Nat Med Date: 2016-07-11 Impact factor: 53.440
Authors: Mary Grace Katusiime; Elias K Halvas; Imogen Wright; Kevin Joseph; Michael J Bale; Bronwyn Kirby-McCullough; Susan Engelbrecht; Wei Shao; Wei-Shau Hu; Mark F Cotton; John W Mellors; Mary F Kearney; Gert U van Zyl Journal: J Virol Date: 2020-01-31 Impact factor: 5.103
Authors: Nitasha A Kumar; Renee M van der Sluis; Talia Mota; Rachel Pascoe; Vanessa A Evans; Sharon R Lewin; Paul U Cameron Journal: J Immunol Date: 2018-07-20 Impact factor: 5.422